Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.29 -1.74%

-$0.25 today

Market cap
$629.58M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.65M

Average 1.02M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$82.23M

FY 2025 · Annual

Investing Cash Flow

-$300.98M

FY 2025 · Annual

Financing Cash Flow

$4.95M

FY 2025 · Annual

-99.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Depreciation & Amortization113K841K1.96M2.06M2.03M
Deferred Income Tax00000
Stock-Based Compensation6.91M17.2M20.01M33.02M40.22M
Change in Working Capital8.84M4.28M(6.55M)685K6.71M
Accounts Receivables8M0000
Inventory831K0000
Accounts Payables2.14M(294K)277K1.58M977K
Other Working Capital(2.13M)4.57M(6.83M)(899K)5.74M
Other Non-Cash Items(169K)(2.18M)(7.69M)(10.59M)(17.57M)
Operating Cash Flow(16.98M)(42.92M)(50.58M)(43.81M)(82.24M)
Capital Expenditures(1.48M)(6.45M)(1.85M)(359K)(1.04M)
Acquisitions (Net)339.48M(64.71M)000
Purchases of Investments(473.63M)(294.39M)(317.34M)(470.58M)(705.22M)
Sales of Investments134.15M359.1M278M212.92M405.28M
Other Investing Activities(339.48M)64.71M000
Investing Cash Flow(340.96M)58.27M(41.19M)(258.02M)(300.98M)
Debt Repayment00000
Common Stock Issued204.17M500K56.53M698.27M5.29M
Common Stock Repurchased0000(347K)
Dividends Paid00000
Other Financing Activities1.81M03.02M14.97M0
Financing Cash Flow386.52M500K59.55M713.24M4.95M
Effect of Forex Changes00000
Net Change in Cash28.59M15.84M(32.22M)411.4M(378.27M)
Free Cash Flow(18.46M)(49.37M)(52.43M)(44.17M)(83.28M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$113.6M
+ D&A$2.0M
+ Stock-Based Comp$40.2M
+ Deferred Tax$0
+ Working Capital$6.7M
- Other Non-Cash-$17.6M
= Operating Cash Flow-$82.2M
- Capex-$1.0M
= Free Cash Flow-$83.3M

Analysis

FY2025 free cash flow is -$83.3M. FCF conversion is 73.3% of net income. Operating cash flow was -$82.2M, with capex of -$1.0M. The largest bridge item is Stock-Based Comp at $40.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 13, 2026

Does JANX generate free cash flow?

Janux Therapeutics, Inc. (JANX) generated -$83.28M of free cash flow in fiscal 2025.

How much operating cash flow does JANX produce?

Operating cash flow was -$82.23M, before capital expenditures of $1.04M.